Systemic sclerosis (scleroderma): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 46
• BCMA 25
• CD20 5
• JAK 0
• STAT3 0
• mTOR 0
• PPAR 0
• PD-1 1
• STING 0
• IL-17 0
• IL-6 0
• NLRP3 0
• CTLA-4 1
• CXCR4 0
• HMGB1 0
• IL-13 0
• IL-4 0
• NRF2 0
• PD-L1 1
• RUNX1 0
• SGLT2 0
• AKT 0
• CD123 0
• CD30 0
• CD38 1
• FGFR 0
• G6PD 0
• GLP-1 0
• HIF-1 0
• IL-15 1
• MMP-9 0
• PARP 0
• PI3K 0
• SIRT1 0
• TLR4 0
• TNF 0
• TP53 0
• TREM2 0
• TYK2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 819 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

  NCT05016804· The Foundation for Orthopaedics and Regenerative Medicine· Updated 20 Oct 2026

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

  NCT06792344· The Children's Hospital of Zhejiang University School of Medicine· Updated 8 Sept 2026

  “temporarily suspended due to no new subjects at present”Registry text, quoted unchanged. Source

• Terminated

  KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

  NCT06400303· Kyverna Therapeutics· Updated 31 Aug 2026

  “Study discontinued due to sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Effect of the Use of Specific Oral Hygiene Devices on Gingival Health Among Patients With Systemic Sclerosis

  NCT04627857· University Hospital, Strasbourg, France· Updated 20 Aug 2026

  “not enough patients”Registry text, quoted unchanged. Source

• Terminated

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 10 Jun 2026

  “The study was closed due to continued enrollment hurdles.”Registry text, quoted unchanged. Source

• Suspended

  A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

  NCT07527936· RenJi Hospital· Updated 4 Jun 2026

  “company's decision”Registry text, quoted unchanged. Source

• Withdrawn

  Implementation of a Biological Sample Collection in Systemic Sclerosis Patients

  NCT04986514· University Hospital, Lille· Updated 4 May 2026

  “withdrawed by the sponsor. A concurrent study is currently underway in the department”Registry text, quoted unchanged. Source

• Suspended

  Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

  NCT06210945· ChemomAb Ltd.· Updated 15 Apr 2026

  “pending financial resources”Registry text, quoted unchanged. Source

• Terminated

  Laser Treatment for the Improvement of Scars and Scleroderma

  NCT04567537· Massachusetts General Hospital· Updated 3 Apr 2026

  “Recruitment has been slow and we are prioritizing other studies.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

  NCT07649265· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· AstraZeneca· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· AstraZeneca· Source

• Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· AstraZeneca AB· Source

• A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

  NCT07873931· Bristol-Myers Squibb· Source

• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Boehringer Ingelheim· Source

• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Novartis Pharmaceuticals· Source

• A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

  NCT07641634· Prolium Bioscience, Inc· Source

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 10
• Mendelian Randomization Analysis 8
• Gene Expression Profiling 14
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 11
• Metabolomics 6
• Mass Spectrometry 2
• Flow Cytometry 9
• Immunohistochemistry 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 26
• Machine Learning 7
• Deep Learning 3
• Cohort Studies 42
• Genome-Wide Association Study 13

• Refining Human Phenotype Ontology (HPO) to enable better phenotype-genotype integration in systemic autoimmune rheumatic diseases.

  Orphanet J Rare Dis, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.